Compounds and methods for inhibiting EMT pathways to treat cancer, organ fibrosis and metabolic disorders
A compound, or a pharmaceutically acceptable salt or isomer thereof, of Formula I: wherein R is hydrogen, alkyl, substituted alkyl, alkenyl, or substituted alkenyl; R 1 is hydrogen, alkoxy, or substituted alkoxy; R 2 is hydrogen, alkyl, or substituted alkyl; and R 3 is hydrogen, alkyl, or substituted alkyl.
1. A compound, or a pharmaceutically acceptable salt or stereoisomer thereof, of Formula I:
wherein R is —(CH 2 ) a —Ar, wherein a is 1 to 6 and Ar is an aryl, substituted aryl, heteroaryl or substituted heteroaryl;
R 1 is hydrogen, alkoxy, or substituted alkoxy;
R 2 is alkyl or substituted alkyl; and
R 3 is hydrogen, alkyl, or substituted alkyl.
2. The compound of claim 1 , wherein Ar is phenyl or substituted phenyl.
3. The compound of claim 1 , wherein R is benzyl or substituted benzyl.
4. The compound of claim 1 , wherein R is benzyl.
5. The compound of claim 1 , wherein R 1 is hydrogen.
6. The compound of claim 1 , wherein R 2 is C 1 -C 6 alkyl.
7. The compound of claim 1 , wherein R 3 is C 1 -C 6 alkyl.
8. The compound of claim 1 , wherein R 3 is ethyl.
9. A pharmaceutical composition comprising a compound of claim 1 , and a pharmaceutically acceptable excipient.
10. The compound of claim 1 , wherein the compound is:
11. The compound of claim 4 , wherein R 2 is C 1 -C 6 alkyl.
12. The compound of claim 11 , wherein R 3 is ethyl.
13. The compound of claim 8 , wherein R 2 is C 1 -C 6 alkyl.
14. The compound of claim 13 , wherein R 3 is ethyl.
15. The compound of claim 1 , wherein R 2 is alkyl.
16. The compound of claim 1 , wherein R 3 is alkyl or substituted alkyl.
17. The compound of claim 16 , wherein R 2 is alkyl or substituted alkyl.
18. The compound of claim 1 , wherein R 2 is pentyl.
19. The compound of claim 2 , wherein R 2 is pentyl.